Clinical trial
Phase I Clinical Study of Irinotecan Liposomes in Combination with Temozolomide and Vincristine in the Treatment of Patients with Relapsed/refractory Pediatric Solid Tumors
NCT06710821 is registered in ClinicalTrials.gov with Yizhuo Zhang as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Clinical Study of Irinotecan Liposomes in Combination with Temozolomide and Vincristine in the Treatment of Patients with Relapsed/refractory Pediatric Solid Tumors
- Lead sponsor
- Yizhuo Zhang
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 1, 2024
- Completion date
- December 31, 2026
- Enrollment
- 40 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor cancer